Blueprint Medicines Corp (BPMC)
106.64
-0.15
(-0.14%)
USD |
NASDAQ |
May 16, 16:00
106.67
+0.03
(+0.03%)
After-Hours: 20:00
Blueprint Medicines Gross Profit Margin (Quarterly): 96.68% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 96.68% |
December 31, 2023 | 99.64% |
September 30, 2023 | 95.08% |
June 30, 2023 | 95.96% |
March 31, 2023 | 94.98% |
December 31, 2022 | 87.50% |
September 30, 2022 | 95.45% |
June 30, 2022 | 86.63% |
March 31, 2022 | 91.90% |
Date | Value |
---|---|
December 31, 2021 | 92.95% |
September 30, 2021 | 84.33% |
June 30, 2021 | 76.21% |
March 31, 2021 | 99.53% |
December 31, 2020 | 99.62% |
September 30, 2020 | 99.98% |
June 30, 2020 | 98.48% |
March 31, 2020 | 99.61% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
76.21%
Minimum
Jun 2021
99.98%
Maximum
Sep 2020
93.80%
Average
95.45%
Median
Sep 2022
Gross Profit Margin (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 90.70% |
Apellis Pharmaceuticals Inc | 88.27% |
Alnylam Pharmaceuticals Inc | 86.65% |
Biomarin Pharmaceutical Inc | 80.71% |
Corcept Therapeutics Inc | 98.27% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -105.3% |
Return on Assets | -26.11% |
Return on Invested Capital | -60.94% |
Profit Margin (Quarterly) | 92.74% |
Operating Margin (Quarterly) | -82.01% |
Return on Net Operating Assets | -162.0% |